Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 May;150(5):1827–1833.

Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

A Huang 1, E R Leygue 1, L Snell 1, L C Murphy 1, P H Watson 1
PMCID: PMC1858197  PMID: 9137105

Abstract

Estrogen receptor (ER) status of breast cancer can be assessed by immunohistochemical assay (IHA), although we have previously observed that ER-IHA levels can be inconsistent between amino-terminal and carboxyl-terminal-targeted antibodies. To address the hypothesis that this discrepancy is attributable to expression of ER variant mRNAs encoding truncated ER-like proteins, we have studied 39 IHA-consistent and 24 IHA-inconsistent breast tumors by reverse transcription polymerase chain reaction to examine the expression of multiple exon-deleted (D-ER) variant mRNAs and the truncated ER clone 4 variant mRNA. ER variants D7-ER, D-3-4-ER, and D4-7-ER were detected at similar frequencies in both groups. However, ER variants D2-3/7-ER, D2-3-4-ER (P < 0.05), and D-3-7-ER (P < 0.01), which encode putative short ER-like proteins that might be recognized only by an amino-terminal-targeted antibody, were preferentially detected in inconsistent cases. ER clone 4 mRNA expression was also higher in inconsistent tumors (P < 0.001). Further analysis showed that, whereas overall prevalence of ER variant mRNAs was similar in both tumor groups, occurrence of the subset of variant mRNAs encoding putative truncated proteins was also higher in IHA-inconsistent tumors (P < 0.05). These data suggest that ER variant mRNAs encoding truncated ER proteins may contribute to discrepancies in ER-IHA levels determined using amino- or carboxyl-terminal-targeted antibodies.

Full text

PDF
1827

Images in this article

1830Figure 3
on p.1830
1831Figure 4
on p.1831

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts S. R., Ingle J. N., Roche P. R., Cha S. S., Wold L. E., Farr G. H., Jr, Krook J. E., Wieand H. S. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996 Aug 15;78(4):764–772. doi: 10.1002/(SICI)1097-0142(19960815)78:4<764::AID-CNCR12>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  2. Allred D. C. Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol. 1993 Jan;99(1):1–3. doi: 10.1093/ajcp/99.1.1. [DOI] [PubMed] [Google Scholar]
  3. Benner S. E., Clark G. M., McGuire W. L. Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci. 1988 Jul;296(1):59–66. doi: 10.1097/00000441-198807000-00011. [DOI] [PubMed] [Google Scholar]
  4. Castles C. G., Fuqua S. A., Klotz D. M., Hill S. M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 1993 Dec 15;53(24):5934–5939. [PubMed] [Google Scholar]
  5. Dotzlaw H., Alkhalaf M., Murphy L. C. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol. 1992 May;6(5):773–785. doi: 10.1210/mend.6.5.1603086. [DOI] [PubMed] [Google Scholar]
  6. Fuqua S. A., Fitzgerald S. D., Allred D. C., Elledge R. M., Nawaz Z., McDonnell D. P., O'Malley B. W., Greene G. L., McGuire W. L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15;52(2):483–486. [PubMed] [Google Scholar]
  7. Fuqua S. A., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W., McGuire W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 1;51(1):105–109. [PubMed] [Google Scholar]
  8. Hiller T., Snell L., Watson P. H. Microdissection RT-PCR analysis of gene expression in pathologically defined frozen tissue sections. Biotechniques. 1996 Jul;21(1):38-40, 42, 44. doi: 10.2144/96211bm07. [DOI] [PubMed] [Google Scholar]
  9. Huang A., Pettigrew N. M., Watson P. H. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol. 1996 Oct;180(2):223–227. doi: 10.1002/(SICI)1096-9896(199610)180:2<223::AID-PATH635>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  10. Leygue E. R., Watson P. H., Murphy L. C. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst. 1996 Mar 6;88(5):284–290. doi: 10.1093/jnci/88.5.284. [DOI] [PubMed] [Google Scholar]
  11. Leygue E., Murphy L., Kuttenn F., Watson P. Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression. Am J Pathol. 1996 Apr;148(4):1097–1103. [PMC free article] [PubMed] [Google Scholar]
  12. Madsen M. W., Reiter B. E., Lykkesfeldt A. E. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol. 1995 Apr 1;109(2):197–207. doi: 10.1016/0303-7207(95)03503-y. [DOI] [PubMed] [Google Scholar]
  13. McGuire W. L., Chamness G. C., Fuqua S. A. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov;5(11):1571–1577. doi: 10.1210/mend-5-11-1571. [DOI] [PubMed] [Google Scholar]
  14. Murphy L. C., Hilsenbeck S. G., Dotzlaw H., Fuqua S. A. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb;1(2):155–159. [PubMed] [Google Scholar]
  15. Murphy L. C., Wang M., Coutt A., Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. J Clin Endocrinol Metab. 1996 Apr;81(4):1420–1427. doi: 10.1210/jcem.81.4.8636345. [DOI] [PubMed] [Google Scholar]
  16. Pertschuk L. P., Feldman J. G., Kim Y. D., Braithwaite L., Schneider F., Braverman A. S., Axiotis C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996 Jun 15;77(12):2514–2519. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2514::AID-CNCR14>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  17. Pfeffer U., Fecarotta E., Castagnetta L., Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res. 1993 Feb 15;53(4):741–743. [PubMed] [Google Scholar]
  18. Pink J. J., Wu S. Q., Wolf D. M., Bilimoria M. M., Jordan V. C. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962–969. doi: 10.1093/nar/24.5.962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Saccani Jotti G., Johnston S. R., Salter J., Detre S., Dowsett M. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol. 1994 Oct;47(10):900–905. doi: 10.1136/jcp.47.10.900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sluyser M. Mutations in the estrogen receptor gene. Hum Mutat. 1995;6(2):97–103. doi: 10.1002/humu.1380060202. [DOI] [PubMed] [Google Scholar]
  21. Sluyser M. Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin Biochem. 1992 Dec;25(6):407–414. doi: 10.1016/0009-9120(92)90015-k. [DOI] [PubMed] [Google Scholar]
  22. Snead D. R., Bell J. A., Dixon A. R., Nicholson R. I., Elston C. W., Blamey R. W., Ellis I. O. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology. 1993 Sep;23(3):233–238. doi: 10.1111/j.1365-2559.1993.tb01195.x. [DOI] [PubMed] [Google Scholar]
  23. Taylor C. R. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer. 1996 Jun 15;77(12):2419–2422. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2419::AID-CNCR1>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  24. Thorpe S. M., Rose C., Rasmussen B. B., Mouridsen H. T., Bayer T., Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987 Nov 15;47(22):6126–6133. [PubMed] [Google Scholar]
  25. Watson P. H., Snell L., Parisien M. The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ. 1996 Aug 1;155(3):281–283. [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES